PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28337636-4	2017	Zymosan-induced DNA-binding activity of nuclear factor-kappa B (NF-kappaB) was attenuated by EVO, which was achieved through inhibitory effects on the phosphorylation of inhibitory kappaB alpha and p65 nuclear translocation, but there was very little association with mitogen-activated protein kinase activation.	evodiamine	93-96	RELA proto-oncogene, NF-kB subunit	Homo sapiens	198-201	
30789361-10	2019	These findings provide evidences that EVO suppresses the migration and invasion of CRC cells by inhibiting the acetyl-NF-kappaB p65 by Sirt1, resulting in suppression of metalloproteinase-9 expression in vitro and in vivo.	evodiamine	38-41	RELA proto-oncogene, NF-kB subunit	Homo sapiens	128-131	
31894007-9	2019	Compared with LPS group, the pre-treatment of evodiamine obviously improved the cell survival rate, promoted the secretion of NO, inhibited the expression of TLR4 and NF-kappaBp65 and down-regulated the mRNA expression of NF-kappaBp65.	evodiamine	46-56	RELA proto-oncogene, NF-kB subunit	Homo sapiens	167-179	
31894007-9	2019	Compared with LPS group, the pre-treatment of evodiamine obviously improved the cell survival rate, promoted the secretion of NO, inhibited the expression of TLR4 and NF-kappaBp65 and down-regulated the mRNA expression of NF-kappaBp65.	evodiamine	46-56	RELA proto-oncogene, NF-kB subunit	Homo sapiens	222-234	
30789361-7	2019	In EVO-induced cells, the intracellular NAD+/NADH ratio was increased, the level of Sirt1 was increased, and acetyl-NF-kappaB P65 was decreased.	evodiamine	3-6	RELA proto-oncogene, NF-kB subunit	Homo sapiens	116-129	
30643424-9	2019	In vivo, combination treatment of the xenograft model with EVO and GEM led to a significant reduction in tumor volume growth and inhibited the activation of NF-kappaB p65 with no obvious adverse reactions.	evodiamine	59-62	RELA proto-oncogene, NF-kB subunit	Homo sapiens	167-170	
30320369-7	2018	The results revealed that Evo dose-dependently reduced the protein and mRNA expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta, and inhibited the levels of phosphorylated (p-) inhibitor of NF-kappaBalpha, p-extracellular signal-regulated kinase, p-c-Jun N-terminal kinase and p-p38, and decreased the nuclear translocation of NF-kappaB/p65 in BEAS-2B cells infected with MSSA.	evodiamine	26-29	RELA proto-oncogene, NF-kB subunit	Homo sapiens	373-376	
26546460-9	2015	Further investigation revealed that evodiamine inhibited the translocation of NF-kappaB p65, which involves the regulation of MMP-2 expression in cancer invasion.	evodiamine	36-46	RELA proto-oncogene, NF-kB subunit	Homo sapiens	78-91	
26590365-0	2016	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-kappaB Pathway in Colorectal Cancer.	evodiamine	0-10	RELA proto-oncogene, NF-kB subunit	Homo sapiens	71-74	
26590365-5	2016	Interestingly, phosphorylation of NF-kappaB pathway, particularly p50/p65, was also inhibited by Evo treatment.	evodiamine	97-100	RELA proto-oncogene, NF-kB subunit	Homo sapiens	70-73